The company's game-changing lead drug candidate against Covid-19 makes NanoViricides, Inc. (NYSE: NNVC) a compelling growth story to zoom in on!
Greetings All,
Covid-19 may not be making as many headlines as it once did, but the world isn't out of the woods yet. Infections and deaths from the virus are still occurring every day in the US, although many people are acting like it's all over.
The virus is still a deadly disease. There are still over 170,000 infections weekly, as well as close to 3,000 hospitalizations and 1,800 deaths in the USA alone. COVID is still the biggest viral public health threat today!
One quietly-trading NYSE company is about to begin clinical trials for a pan-coronavirus drug to help defeat the virus once and for all…. put NanoViricides Inc. (NYSE: NNVC) on your radar!
This leading biopharmaceutical company is developing nanotechnology-based antiviral therapeutics and has been working on a pan-coronavirus antiviral to fulfill an unmet medical need.
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. Imagine a pan-coronavirus drug that is safe enough to be used by anyone and is highly effective remains an unmet medical need….. That's what NNVC is developing.
The company has been a drug discovery company for many years while it has looked to perfect its patented nanoviricide technology, a platform technology that deploys a novel mechanism to combat viruses.
With this unique technology, NNVC has reported developing a strong R&D pipeline of many antiviral drugs. It's no surprise that the company boasts a $5.25 price target!
This price target represents a +352.59% increase from the last price of 1.16.
So why pay attention to NNVC in particular?
The company is transitioning into becoming a clinical-stage pharmaceutical company and its clinical trials of NV-CoV-2, the Company's pan-coronavirus drug, are now imminent!
The drug has already successfully completed the preclinical safety and effectiveness studies, and the Company has already set up cGMP manufacturing for the clinical drug products.
The best part? NNVC's drug may work against all current and future Covid variants!
NV-CoV-2 is a broad-spectrum antiviral that looks to treat most human coronaviruses and will maintain its effectiveness as the variants mutate. This may mark a major step in the fight to find a permanent solution to COVID.
Developing a drug that works against multiple COVID variants is key because as each variant mutates and spreads it has the risk of further widespread outbreaks causing an endemic or even a future pandemic.
This may be the most exciting time to be paying attention to NNVC.
The company's lead coronavirus drug candidate could become a game changer in fighting the virus and could quickly put NNVC on the map!
NV-CoV-2 was found to work against many unrelated coronaviruses. So variants of SARS-CoV-2 (that causes COVID) are highly unlikely to be able to escape it!
http://www.nanoviricides.com/
NanoViricides, Inc.
NYSE: NNVC
A New Era in Targeted Anti-Viral Therapeutics.
NanoViricides, Inc. (NYSE: NNVC) is a development stage company moving to clinical-stage that is creating special purpose nanomaterials for antiviral therapy.
The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.
Their platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses.
NV-CoV-2:
NanoViricides, Inc. (NYSE: NNVC) is pursuing a clinical trial application for its lead drug candidate for the treatment of COVID-19, NV-CoV-2. This drug candidate is designed to act by a novel mechanism of action, that they call "Re-infection Blocker".
NV-CoV-2 was found to be a broad-spectrum, pan-coronavirus drug candidate in pre-clinical studies.
NanoViricides Drug NV-CoV-2 is Unique
Antiviral medication is an important way of coping with viral infections, other than vaccines and antibodies, as we all know from HIV. These drugs help the body fight off infection at the cellular level.
Many people have no idea that there are significant issues with the antivirals currently on the market for treating COVID. These include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD), which either have limited effectiveness in treating the disease or carry the risk of serious side effects or both. Of note, they all have significant limitations on which category of patients can be helped.
Unlike the existing COVID drugs, NanoViricides' drug NV-CoV-2 caters to the needs of ALL patients.
The Company has developed oral syrup and oral gummies for use in mild to moderate disease (out-patients). It has developed an injectable solution that can be injected, inhaled or infused, for use in severely ill or hospitalized patients. Having these multiple formulations gives the drug a broad range of applications.
The company also has the ability to manufacture clinical quantities of the drug products for clinical trials in its own "current Good Manufacturing Practices (cGMP)"-compliant facility, enabling time and cost savings.
NanoViricides, Inc. (NYSE: NNVC) is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility!
The global antiviral market was worth $48.1 billion in 2018 and is expected to grow to $79.8 billion at a compound annual growth rate (CAGR) of 6.7% from 2019 to 2026. It's obvious the market is lucrative and allows NNVC to zoom in on a tremendous population.
MORE REASONS TO HAVE NNVC ON YOUR RADAR INCLUDE:
- The company is led by the renowned inventor of nanoviricides technology, Dr. Anil Diwan, and is managed by a highly effective team who have decades of entrepreneurial, pharmaceutical, and nanomedicine experience.
- Strong P&E assets comprise the company's cGMP-capable manufacturing and R&D facility.
- The company's drug products could significantly change the world if and they contend when hit the market.
- Over 15+ years of experience in nanomedicine and antiviral therapy developments.
- Fast moving drug candidate developments for the treatment of SARS-CoV-2 in patients.
- A strong, diverse, and promising product pipeline that addresses the world's most infamous and infectious viruses.
- The antiviral therapy and nanomedicine market is expected to experience exponential growth in the coming years as more viruses emerge.
- The company's developments are sustainable beyond COVID-19 as their diverse product pipeline targets several markets simultaneously:
As COVID-19 continues to spread across the globe, increased demand for nanomedicine has led to the strong growth of the global nanomedicine market.
NNVC reported that as of December 31, 2022, they had cash and cash equivalent current assets balance of approximately $11.5 Million. In addition, they reported approximately $8.4 Million in Property and Equipment (P&E) assets, net of depreciation and amortization from $14.7 Million in P&E assets before depreciation. The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT.
The company believes they have sufficient funds to complete initial human clinical trials for NV-CoV-2.
NV-CoV-2 addresses the unmet need for a safe and effective treatment that can be used in otherwise healthy patients as well as in children, based on its strong safety and effectiveness observed in animal studies.
With production of the drug now underway, NNVC could quickly start gaining Wall Street attention and with a $5.25 price target, may see upside in the TRIPLE DIGITS!
No comments:
Post a Comment